Vitamin K1 in the Treatment of Spontaneous Intracerebral Hemorrhage
Status:
Unknown status
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
In order to determine the effectiveness and safety of early vitamin K1 use in reducing the
risk of bleeding and improving prognosis in patients with spontaneous intracerebral
hemorrhage. Patients with spontaneous intracerebral hemorrhage (excluding rupture of aneurysm
and vascular malformation) will be randomly divided into experimental group and control
group. All the patients in the two groups were treated according to the guideline of
spontaneous intracerebral hemorrhage. Patients in the experimental group was treated with
intravenous injection of vitamin K1 20mg once a day for 2 days after admission, and the
patients in control group was treated with normal saline as a control. The hematoma volume,
coagulation function, platelet levels and GCS scales of the two groups will be recorded in
0d, 1d, 3d, 7d post bleeding stroke, furthermore, length of ICU stay and total
hospitalization, incidence of complications during hospitalization are to be recorded. During
the follow-up, mRS score will be recorded at 1m and 6m post bleeding stroke.